Source: Allergan PLC agreed to acquire clinical-stage biotechnology company Vitae Pharmaceuticals Inc. for $639 million, more than double its market value, in a move aimed at strengthening the drugmaker’s skin-care pipeline. The price values Vitae at $21 a share, compared with the company’s closing price of $8.10 on Tuesday. Vitae…...